<p>Rani Therapeutics（纳斯达克代码：RANI - 获取免费报告）于周四发布了季度财报。该公司报告每股收益（EPS）为（$0.12），低于分析师一致预期的（$0.09），差距为（$0.03），FiscalAI 报道。</p>
<p>获取 <strong>Rani Therapeutics</strong> 的提醒：</p>
<h2>Rani Therapeutics 股票表现</h2>
<p>纳斯达克 RANI 周五下跌 $0.25，报 $2.02。该股票的交易量为 6,407,335 股，而其平均交易量为 53,376,040 股。Rani Therapeutics 的 12 个月低点为 $0.39，12 个月高点为 $3.87。该公司的 50 日移动平均价格为 $1.00，200 日移动平均价格为 $0.75。该股票的市值为 $145.18 百万，市盈率为 -2.56，贝塔值为 0.38。</p>
<h2>内部活动</h2>
<p>在其他 Rani Therapeutics 的新闻中，主要股东 South Cone Investments Limited 于 10 月 21 日（星期二）出售了 4,000,000 股 Rani Therapeutics 股票。该股票以平均价格 $2.77 出售，总交易额为 $11,080,000.00。交易完成后，内部人士持有该公司 2,379,194 股，估值约为 $6,590,367.38。此次交易使其持股减少了 62.70%。该出售在与 SEC 的法律文件中披露，您可以通过此链接访问。此外，董事 Mir A. Imran 于 10 月 23 日（星期四）购买了 2,083,334 股该股票。该股票以每股平均成本 $0.60 购买，总价值为 $1,250,000.40。交易完成后，该董事直接持有该公司 2,083,334 股，估值为 $1,250,000.40。此次交易代表其持股的 ∞ 增加。该购买的披露在 SEC 文件中可用。公司内部人士持有 45.08% 的股票。</p>
<h2>机构资金流入和流出</h2>
<p>一家对冲基金最近在 Rani Therapeutics 股票中购买了新股份。Armistice Capital LLC 在第二季度购买了 Rani Therapeutics Holdings, Inc.（纳斯达克代码：RANI - 免费报告）的新头寸，根据其最近向证券交易委员会的文件。该基金购买了 3,151,354 股该公司的股票，估值约为 $1,619,000。Armistice Capital LLC 在最近的报告期末持有 Rani Therapeutics 约 4.99% 的股份。对冲基金和其他机构投资者持有该公司 30.19% 的股票。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家券商对 RANI 发表了评论。Maxim Group 将 Rani Therapeutics 的股票目标价从 $5.00 上调至 $10.00，并在 10 月 20 日（星期一）的研究报告中给予该股票 &#34;买入&#34; 评级。HC Wainwright 在 10 月 21 日（星期二）的研究报告中重申了 &#34;买入&#34; 评级，并设定了 $11.00 的目标价。Wall Street Zen 在 8 月 16 日（星期六）的报告中将 Rani Therapeutics 的股票评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。最后，Weiss Ratings 在 10 月 31 日（星期五）的研究报告中重申了 Rani Therapeutics 的 &#34;卖出（d-）&#34; 评级。四位研究分析师对该股票给予了买入评级，一位则对该公司发布了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，平均目标价为 $8.50。</p>
<p><strong>阅读我们关于 Rani Therapeutics 的最新股票报告</strong></p>
<h2>Rani Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Rani Therapeutics Holdings, Inc. 作为一家临床阶段的生物治疗公司，开发用于美国患者、医生和医疗系统的口服生物制剂。该公司开发了 RaniPill 胶囊，这是一种药物无关的口服递送平台，用于递送多种药物成分，包括寡核苷酸、肽、蛋白质和抗体。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Rani Therapeutics</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>OpenAI 的重组为可能成为有史以来最大 IPO 的机会铺平了道路</li>
<li>如何做空纳斯达克：易于遵循的指南</li>
<li>美国政府不希望失败的 2 只稀土股票</li>
<li>宠物是大生意：4 只大票宠物股票可加入您的投资组合</li>
<li>CrowdStrike 与 CoreWeave 合作，但投资者抛售消息</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFOSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFOSQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 $1,000 在 Rani Therapeutics 吗？</h2>
<p>在考虑 Rani Therapeutics 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Rani Therapeutics 并不在名单上。</p>
<p>虽然 Rani Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

RANI

<p>Rani Therapeutics（纳斯达克代码：RANI）报告的季度收益为每股亏损 0.12 美元，低于预期的每股亏损 0.09 美元，差距为 0.03 美元。股价下跌至 2.02 美元，市值为 1.4518 亿美元。主要股东南美投资公司出售了 400 万股，而董事 Mir A. Imran 购买了 208 万股。机构持股比例为 30.19%。分析师的评级不一，目标价格范围在 5.00 美元到 11.00 美元之间，反映出 “适度买入” 的平均评级</p>

<p>Rani Therapeutics (NASDAQ:RANI - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.03), FiscalAI reports.</p>
<div class="lb-trans"><p>Rani Therapeutics（纳斯达克代码：RANI - 获取免费报告）于周四发布了季度财报。该公司报告每股收益（EPS）为（$0.12），低于分析师一致预期的（$0.09），差距为（$0.03），FiscalAI 报道。</p>
</div><p>Get <strong>Rani Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Rani Therapeutics</strong> 的提醒：</p>
</div><h2>Rani Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Rani Therapeutics 股票表现</h2>
</div><p>NASDAQ RANI traded down $0.25 on Friday, reaching $2.02. The stock had a trading volume of 6,407,335 shares, compared to its average volume of 53,376,040. Rani Therapeutics has a 12-month low of $0.39 and a 12-month high of $3.87. The business's 50-day moving average price is $1.00 and its 200 day moving average price is $0.75. The stock has a market cap of $145.18 million, a P/E ratio of -2.56 and a beta of 0.38.</p>
<div class="lb-trans"><p>纳斯达克 RANI 周五下跌 $0.25，报 $2.02。该股票的交易量为 6,407,335 股，而其平均交易量为 53,376,040 股。Rani Therapeutics 的 12 个月低点为 $0.39，12 个月高点为 $3.87。该公司的 50 日移动平均价格为 $1.00，200 日移动平均价格为 $0.75。该股票的市值为 $145.18 百万，市盈率为 -2.56，贝塔值为 0.38。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other Rani Therapeutics news, major shareholder South Cone Investments Limited sold 4,000,000 shares of Rani Therapeutics stock in a transaction dated Tuesday, October 21st. The shares were sold at an average price of $2.77, for a total transaction of $11,080,000.00. Following the completion of the transaction, the insider owned 2,379,194 shares in the company, valued at approximately $6,590,367.38. The trade was a 62.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Mir A. Imran bought 2,083,334 shares of the stock in a transaction on Thursday, October 23rd. The stock was purchased at an average cost of $0.60 per share, with a total value of $1,250,000.40. Following the completion of the purchase, the director directly owned 2,083,334 shares in the company, valued at $1,250,000.40. This trade represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. 45.08% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在其他 Rani Therapeutics 的新闻中，主要股东 South Cone Investments Limited 于 10 月 21 日（星期二）出售了 4,000,000 股 Rani Therapeutics 股票。该股票以平均价格 $2.77 出售，总交易额为 $11,080,000.00。交易完成后，内部人士持有该公司 2,379,194 股，估值约为 $6,590,367.38。此次交易使其持股减少了 62.70%。该出售在与 SEC 的法律文件中披露，您可以通过此链接访问。此外，董事 Mir A. Imran 于 10 月 23 日（星期四）购买了 2,083,334 股该股票。该股票以每股平均成本 $0.60 购买，总价值为 $1,250,000.40。交易完成后，该董事直接持有该公司 2,083,334 股，估值为 $1,250,000.40。此次交易代表其持股的 ∞ 增加。该购买的披露在 SEC 文件中可用。公司内部人士持有 45.08% 的股票。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A hedge fund recently bought a new stake in Rani Therapeutics stock. Armistice Capital LLC bought a new position in Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 3,151,354 shares of the company's stock, valued at approximately $1,619,000. Armistice Capital LLC owned approximately 4.99% of Rani Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.19% of the company's stock.</p>
<div class="lb-trans"><p>一家对冲基金最近在 Rani Therapeutics 股票中购买了新股份。Armistice Capital LLC 在第二季度购买了 Rani Therapeutics Holdings, Inc.（纳斯达克代码：RANI - 免费报告）的新头寸，根据其最近向证券交易委员会的文件。该基金购买了 3,151,354 股该公司的股票，估值约为 $1,619,000。Armistice Capital LLC 在最近的报告期末持有 Rani Therapeutics 约 4.99% 的股份。对冲基金和其他机构投资者持有该公司 30.19% 的股票。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages have commented on RANI. Maxim Group lifted their price objective on shares of Rani Therapeutics from $5.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a research note on Monday, October 20th. HC Wainwright reissued a &#34;buy&#34; rating and set a $11.00 price target on shares of Rani Therapeutics in a research report on Tuesday, October 21st. Wall Street Zen raised shares of Rani Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Rani Therapeutics in a research report on Friday, October 31st. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $8.50.</p>
<div class="lb-trans"><p>多家券商对 RANI 发表了评论。Maxim Group 将 Rani Therapeutics 的股票目标价从 $5.00 上调至 $10.00，并在 10 月 20 日（星期一）的研究报告中给予该股票 &#34;买入&#34; 评级。HC Wainwright 在 10 月 21 日（星期二）的研究报告中重申了 &#34;买入&#34; 评级，并设定了 $11.00 的目标价。Wall Street Zen 在 8 月 16 日（星期六）的报告中将 Rani Therapeutics 的股票评级从 &#34;卖出&#34; 上调至 &#34;持有&#34;。最后，Weiss Ratings 在 10 月 31 日（星期五）的研究报告中重申了 Rani Therapeutics 的 &#34;卖出（d-）&#34; 评级。四位研究分析师对该股票给予了买入评级，一位则对该公司发布了卖出评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 &#34;适度买入&#34;，平均目标价为 $8.50。</p>
</div><p><strong>Read Our Latest Stock Report on Rani Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Rani Therapeutics 的最新股票报告</strong></p>
</div><h2>Rani Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Rani Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.</p>
<div class="lb-trans"><p>Rani Therapeutics Holdings, Inc. 作为一家临床阶段的生物治疗公司，开发用于美国患者、医生和医疗系统的口服生物制剂。该公司开发了 RaniPill 胶囊，这是一种药物无关的口服递送平台，用于递送多种药物成分，包括寡核苷酸、肽、蛋白质和抗体。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Rani Therapeutics</li>
<li>Best ESG Stocks: 11 Best Stocks for ESG Investing</li>
<li>OpenAI's Restructuring Sets up What Could Be the Biggest IPO Ever</li>
<li>How to Short Nasdaq: An Easy-to-Follow Guide</li>
<li>2 Rare Earth Stocks the U.S. Government Doesn’t Want to Fail</li>
<li>Pets Are Big Business: 4 Big-Ticket Pet Stocks to Add to Your Portfolio</li>
<li>CrowdStrike Partners With CoreWeave But Investors Sell the News</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Rani Therapeutics</li>
<li>最佳 ESG 股票：11 只最佳 ESG 投资股票</li>
<li>OpenAI 的重组为可能成为有史以来最大 IPO 的机会铺平了道路</li>
<li>如何做空纳斯达克：易于遵循的指南</li>
<li>美国政府不希望失败的 2 只稀土股票</li>
<li>宠物是大生意：4 只大票宠物股票可加入您的投资组合</li>
<li>CrowdStrike 与 CoreWeave 合作，但投资者抛售消息</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFOSQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=RANI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rani Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Rani Therapeutics 吗？</h2>
</div><p>Before you consider Rani Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Rani Therapeutics 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买... 而 Rani Therapeutics 并不在名单上。</p>
</div><p>While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Rani Therapeutics 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Rani Therapeutics (NASDAQ:RANI) 公布季度财报，每股收益比预期低 0.03 美元